Literature DB >> 35590046

Knockdown of Circ_0003506 Impedes Radioresistance, Cell Growth, Migration and Invasion in Gastric Cancer.

Kaikai Zhou1, Jianwen Zhang1, Shunxin Song1, Kaihong Xie2, Xiaonan Hu3.   

Abstract

BACKGROUND: Radioresistance is a major obstacle for clinical treatment of gastric cancer (GC). has_circ_0003506 (circ_0003506) was reported as an oncogenic factor in GC, but its effect on radioresistant GC is unclear. AIMS: This study aimed to explore the role of circ_0003506 in radioresistance and regulatory mechanism.
METHODS: The expression detection was performed by real-time polymerase chain reaction. Cell survival was analyzed by colony formation assay. Cell proliferation was measured by Cell Counting Kit-8 assay and colony formation assay. Cell migration and invasion were examined using transwell assay. Cell apoptosis was assessed by flow cytometry. The target binding was confirmed via dual-luciferase reporter assay. The protein level was determined through western blot. Animal assay was performed for the functional exploration of circ_0003506 on radiosensitivity in vivo.
RESULTS: Circ_0003506 was upregulated in radioresistant GC cells. Downregulation of circ_0003506 inhibited radioresistance to repress proliferation, migration and invasion but increase apoptosis in radioresistant GC cells. Circ_0003506 was a sponge of miR-1256. The effects of si-circ_0003506 on radioresistant GC cells were reverted by miR-1256 inhibitor. MiR-1256 suppressed tumor progression in radioresistant GC cells by downregulating bone morphogenetic protein type 2 receptor. Circ_0003506 regulated the level of bone morphogenetic protein type 2 receptor by targeting miR-1256. Downregulating circ_0003506 increased radiosensitivity of GC in vivo via regulating miR-1256 and bone morphogenetic protein type 2 receptor.
CONCLUSION: Knockdown of circ_0003506 suppressed radioresistance in GC through the regulation of miR-1256/bone morphogenetic protein type 2 receptor axis. Circ_0003506 might be a therapeutic target in radiotherapy of GC.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  BMPR2; Circular RNA; MicroRNA; Radioresistance; Stomach neoplasms

Year:  2022        PMID: 35590046     DOI: 10.1007/s10620-022-07534-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

1.  Circular RNA hsa_circ_0000993 inhibits metastasis of gastric cancer cells.

Authors:  Shanliang Zhong; Jinyan Wang; Junchen Hou; Qian Zhang; Hanzi Xu; Jiahua Hu; Jianhua Zhao; Jifeng Feng
Journal:  Epigenomics       Date:  2018-09-14       Impact factor: 4.778

2.  Circular RNA hsa_circRNA_102958 may serve as a diagnostic marker for gastric cancer.

Authors:  Juan Wei; Wei Wei; Hanfeng Xu; Zhaojing Wang; Wen Gao; Tianjun Wang; Qin Zheng; Yongqian Shu; Wei De
Journal:  Cancer Biomark       Date:  2020       Impact factor: 4.388

Review 3.  Circular RNA: An emerging non-coding RNA as a regulator and biomarker in cancer.

Authors:  Bing Chen; Shenglin Huang
Journal:  Cancer Lett       Date:  2018-01-09       Impact factor: 8.679

4.  Gastric cancer: epidemiology, biology, and prevention: a mini review.

Authors:  Kiara Lyons; Linh C Le; Yen T-H Pham; Claire Borron; Jong Y Park; Chi T D Tran; Thuan V Tran; Huong T-T Tran; Khanh T Vu; Cuong D Do; Claudio Pelucchi; Carlo La Vecchia; Janice Zgibor; Paolo Boffetta; Hung N Luu
Journal:  Eur J Cancer Prev       Date:  2019-09       Impact factor: 2.497

Review 5.  Progress of preoperative and postoperative radiotherapy in gastric cancer.

Authors:  Nan Zhang; Qian Fei; Jiajia Gu; Li Yin; Xia He
Journal:  World J Surg Oncol       Date:  2018-09-13       Impact factor: 2.754

6.  Palliative radiotherapy in symptomatic locally advanced gastric cancer: A phase II trial.

Authors:  Jeremy Tey; Huili Zheng; Yu Y Soon; Cheng N Leong; Wee Y Koh; Keith Lim; Jimmy B Y So; Asim Shabbir; Ivan W K Tham; Jiade Lu
Journal:  Cancer Med       Date:  2019-02-20       Impact factor: 4.452

Review 7.  Role of non-coding RNAs and RNA modifiers in cancer therapy resistance.

Authors:  Xinyi Zhang; Kai Xie; Honghua Zhou; Yuwei Wu; Chan Li; Yating Liu; Zhaoya Liu; Qian Xu; Shuang Liu; Desheng Xiao; Yongguang Tao
Journal:  Mol Cancer       Date:  2020-03-02       Impact factor: 27.401

8.  Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer.

Authors:  Birendra Kumar Sah; Benyan Zhang; Huan Zhang; Jian Li; Fei Yuan; Tao Ma; Min Shi; Wei Xu; Zhenglun Zhu; Wentao Liu; Chao Yan; Chen Li; Bingya Liu; Min Yan; Zhenggang Zhu
Journal:  Nat Commun       Date:  2020-11-30       Impact factor: 14.919

Review 9.  Circular RNAs: Potential Regulators of Treatment Resistance in Human Cancers.

Authors:  Shivapriya Jeyaraman; Ezanee Azlina Mohamad Hanif; Nurul Syakima Ab Mutalib; Rahman Jamal; Nadiah Abu
Journal:  Front Genet       Date:  2020-01-28       Impact factor: 4.599

View more
  1 in total

Review 1.  Functions of the bone morphogenetic protein signaling pathway through non-coding RNAs.

Authors:  Ural Mukhametov; Sergey Lyulin; Dmitry Borzunov; Galina Sufianova; Alina Shumadalova; Daming Zhang; Ilgiz Gareev
Journal:  Noncoding RNA Res       Date:  2022-07-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.